VIDEO: Preclinical research investigates role of Claudin-1 in cholangiocarcinoma
Click Here to Manage Email Alerts
BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about research assessing the role of Claudin-1 in cholangiocarcinoma, which was presented at The Liver Meeting.
In a preclinical study, researchers sought to determine whether exposed Claudin-1 can act as a therapeutic target in the treatment of cholangiocarcinoma. They performed proof-of-concept studies using humanized monoclonal antibodies in cell line-derived and patient-derived xenograft mouse models.
The researchers reported that Claudin-1 is a driver for cholangiocarcinoma invasion and metastasis.
“This study has not been assessed clinically, but I think it should be,” Boyer, Ensign Professor of Medicine and emeritus director of the Liver Center at Yale School of Medicine, said. “The data that [the research group] has is very impressive.”
Reference:
- Nehme Z, et al. Claudin-1 mediates cholangiocellular carcinoma invasion and metastasis by reprogramming the tumor microenvironment. Presented at: The Liver Meeting; Nov. 10-14, 2023; Boston (hybrid meeting).
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts